Skip to main content

Table 1 Baseline characteristics in 28 patients. Values are reported as frequency (n [%]) or as mean (range)

From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

Characteristic

Number of patients (percent)

Age, yrs

  ≤ 59

13 (46.4)

  > 59

15 (53.6)

Primary tumor location

 Ovary

26 (92.9)

 Fallopian tube

2 (7.1)

 Peritoneum

0 (0)

International FIGO stage

 I

4 (14.3)

 II

2 (7.1)

 III

19 (67.9)

 IV

3 (10.7)

Histological type

 Serous

25 (89.3)

 Endometrioid

1 (3.6)

 Mixed serous and endometrioid

1 (3.6)

 Mixed serous and mucious

1 (3.6)

Family history of cancer

 Yes

10 (35.7)

 No

15 (53.6)

 Missing data

3 (10.7)

ECOG

 0

18 (64.3)

 1

10 (35.7)

BRCA

 BRCA 1/2 mutation

11 (39.3)

 Wild type

11 (39.3)

 Unknown

6 (21.4)

Sensitivity to platinum-based chemotherapy

 Platinum-sensitive

11 (39.3)

 Platinum-resistant

13 (46.4)

 Unknown

4 (14.3)

Categories of therapy

 First-line maintenance therapy

2 (7.1)

 Second-line maintenance therapy

10 (35.7)

 Treatment after multi-line chemotherapy

6 (21.4)

 Exploratory therapy

10 (35.7)

Primary cytoreductive surgery

 Yes

27 (96.4)

 No

1 (3.6)

Secondary cytoreductive surgery

 Yes

6 (21.4)

 No

22 (78.6)

Combination of anti-angiogenic agents

 Yes

4 (14.3)

 No

24 (85.7)

  1. Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; ECOG, Eastern Cooperative Oncology Group